What is Mabwell?
Mabwell operates as an R&D-driven biopharmaceutical powerhouse, distinguished by its comprehensive portfolio of over 10 biologics pipelines. The company has engineered a sophisticated technological infrastructure, featuring high-throughput screening platforms for hybridoma antibodies, advanced B cell screening, and specialized ADC drug development capabilities. By integrating PEGylation technology and bispecific antibody development, Mabwell maintains a vertically integrated model that spans the entire value chain from molecular discovery to commercialization. This technical depth positions the firm as a leader in addressing unmet medical needs through precision medicine and innovative therapeutic modalities.
How much funding has Mabwell raised?
Mabwell has raised a total of $825.9M across 2 funding rounds:
Series A
$278M
Stock Offering
$547.9M
Series A (2020): $278M with participation from Shenzhen Shiyu Investment Management, Oriental Fortune Capital, Loyal Valley Capital, and Haitong Capital
Stock Issuance/Offering (2022): $547.9M, investors not publicly disclosed
Key Investors in Mabwell
Oriental Fortune Capital
A prominent investment firm focusing on high-growth sectors including healthcare and advanced manufacturing in the Chinese market.
Loyal Valley Capital
A private equity firm that specializes in long-term value creation by backing industry-leading companies in the technology and healthcare sectors.
Shenzhen Shiyu Investment Management
An investment management entity focused on strategic asset allocation and supporting innovation-driven enterprises within the life sciences industry.
What's next for Mabwell?
Looking ahead, Mabwell is poised to leverage its recent capital injection to transition from a research-heavy organization to a commercial-stage leader. The strategic roadmap focuses on the clinical advancement of its diverse pipeline, with a particular emphasis on scaling manufacturing capacity to meet global demand. By optimizing its proprietary R&D engine, the company aims to shorten the time-to-market for its lead candidates in ophthalmology and infectious diseases. Investors and industry analysts will be closely monitoring the firm's ability to convert its robust technological platform into tangible market share, as it navigates the complexities of international regulatory environments and competitive biopharmaceutical markets.
See full Mabwell company page
